Minyi Cheng
Impact in
- Cancer Research top 10%
- Breast Cancer Treatment Studies
-
- Enzyme Production and Characterization
Papers in
-
- Breast Cancer Treatment Studies 16
- Oncology 16
- Cancer Treatment and Pharmacology 6
- Cancer Cells and Metastasis 4
- HER2/EGFR in Cancer Research 3
- PARP inhibition in cancer therapy 3
- Co-authors
- Teng Zhu (33 shared papers)Kun Wang (34 shared papers)Liulu Zhang (33 shared papers)Fei Ji (25 shared papers)Hongfei Gao (25 shared papers)Mei Yang (22 shared papers)Ciqiu Yang (13 shared papers)Ying Lin (6 shared papers)
In The Last Decade
Minyi Cheng
41 papers receiving 514 citations
Minyi Cheng's Hit Papers
Peers
Comparison fields: 5 of 60
- Cancer Research 156
- Biotechnology 45
- Oncology 104
- Radiology, Nuclear Medicine and Imaging 80
- Health Informatics 3
Countries citing papers authored by Minyi Cheng
This map shows the geographic impact of Minyi Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minyi Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minyi Cheng more than expected).
Fields of papers citing papers by Minyi Cheng
This network shows the impact of papers produced by Minyi Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minyi Cheng. The network helps show where Minyi Cheng may publish in the future.
Co-authors
The 25 scholars most cited alongside Minyi Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study Hit paper breakdown → | 2023 | 104 |
| 2 | 2021 | 44 | |
| 3 | 2018 | 38 | |
| 4 | 2020 | 32 | |
| 5 | 2009 | 24 | |
| 6 | 2009 | 23 | |
| 7 | 2023 | 20 | |
| 8 | 2020 | 20 | |
| 9 | 2019 | 19 | |
| 10 | 2021 | 15 | |
| 11 | 2022 | 14 | |
| 12 | 2025 | 14 | |
| 13 | 2021 | 14 | |
| 14 | 2022 | 11 | |
| 15 | 2020 | 9 | |
| 16 | 2020 | 9 | |
| 17 | 2022 | 8 | |
| 18 | 2022 | 8 | |
| 19 | 2009 | 8 | |
| 20 | 2020 | 7 |
About Minyi Cheng
Minyi Cheng is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 44 papers that have together received 519 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (16 papers), Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (6 papers), Cancer Cells and Metastasis (4 papers), HER2/EGFR in Cancer Research (3 papers), PARP inhibition in cancer therapy (3 papers), Radiomics and Machine Learning in Medical Imaging (3 papers) and DNA Repair Mechanisms (2 papers). The work is most often cited by research in Cancer Research (156 citations), Biotechnology (45 citations), Oncology (104 citations), Radiology, Nuclear Medicine and Imaging (80 citations) and Health Informatics (3 citations). Minyi Cheng has collaborated with scholars based in China, Hong Kong and Japan. Frequent co-authors include Teng Zhu, Kun Wang, Liulu Zhang, Fei Ji, Hongfei Gao, Mei Yang, Ciqiu Yang, Ying Lin, Zhi‐Yong Wu and Jieqing Li. Their work appears in journals such as Therapeutic Advances in Medical Oncology, The Breast, Journal of Clinical Oncology, International Journal of Cancer and Journal of Surgical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.